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Peptides presented by major histocompatibility complex class II (MHCII) molecules to
CD4+T cells play a central role in the initiation of adaptive immunity. This antigen presen-
tation process is characterized by the proteolytic cleavage of foreign and self proteins, and
loading of the resultant peptides onto MHCII molecules. Loading and exchange of antigenic
peptides is catalyzed by a non-classical MHCII molecule, HLA-DM.The impact of HLA-DM
on epitope selection has been appreciated for a long time. However, the molecular mech-
anism by which HLA-DM mediates peptide exchange remains elusive. Here, we review
recent efforts in elucidating how HLA-DM works, highlighted by two recently solved co-
structures of HLA-DM bound to HLA-DO (a natural inhibitor of HLA-DM), or to HLA-DR1 (a
common MHCII). In light of these efforts, a model for HLA-DM action in which HLA-DM
utilizes conformational flexibility around the P1 pocket of the MHCII-peptide complex to
catalyze peptide exchange is proposed.
Keywords: antigen presentation, epitope selection, MHCII-peptide complex, HLA-DM susceptibility, hydrogen
bonds, conformational heterogeneity
INTRODUCTION
Major histocompatibility complex class II (MHCII) proteins are
expressed constitutively on the surface of professional antigen-
presenting cells, and induced by inflammatory stimuli on many
other cell types. They display peptides derived from self or for-
eign antigens for recognition by CD4+ T cells to initiate and
regulate many aspects of adaptive immunity. Newly synthesized
MHCII molecules associate with the invariant chain chaperone,
which directs nascent MHCII to endosomal compartments before
degradation by endosomal-resident cathepsin proteases, leaving
small peptide fragments known as CLIP (class II-associated invari-
ant chain peptide) bound in the MHCII-peptide binding groove
(1–7). The release of CLIP and subsequent loading of antigenic
peptides onto MHCII is catalyzed by a non-classical MHCII mol-
ecule, HLA-DM (8). HLA-DM also serves as a peptide editor by
mediating the exchange of bound antigenic peptides, selecting for
presentation of peptides with higher kinetic stability (9).
HLA-DM-mediated peptide exchange has been shown to play
a key role in epitope selection. It has been found that HLA-DM
extinguishes the presentation of cryptic epitopes and stimulates
the presentation of immunodominant epitopes (10), and that the
effects of HLA-DM editing can be altered by manipulation of the
kinetic stability of MHCII-peptide complexes (11). We and oth-
ers have demonstrated that the kinetic stability of MHCII-peptide
complexes in the presence of HLA-DM directly correlates with
immunogenicity (12–14). However, some immunodominant epi-
topes are found to have low affinities and low kinetic stabilities;
notably most derive from self-antigens and are often associated
in autoimmune diseases (15–18). In these cases, it is possible that
self-peptides bound to MHCII alleles escaped HLA-DM editing
due to downregulation, inhibition, or deficiency of HLA-DM in
antigen presenting cells. This idea is supported by the observation
that expression of HLA-DM decreased significantly in rheumatoid
arthritis patients (19).
Due to the key role of HLA-DM in selection of both foreign
pathogenic epitopes and autoimmune self-reactive epitopes, the
mechanism of HLA-DM-mediated peptide exchange has been
studied intensively. Here, we review the literature on efforts to
determine how HLA-DM mediates peptide exchange and focus
on two recent co-structures of HLA-DM in complex with MHCII
binding partners.
INVOLVEMENT AND CONTRIBUTION OF HYDROGEN BONDS
TO HLA-DM SUSCEPTIBILITY
The hydrogen bond network between peptide backbone and
MHCII main chain (α51–α53) or conserved MHCII side-chain
(α62, α69, β61, β81, and β82) residues, together with peptide side-
chain binding P1, P4, P6, and P9 pockets are a characteristic feature
of MHCII-peptide interaction (20, 21). The ability of HLA-DM to
catalyze the exchange of a wide variety of peptides implicated the
hydrogen bond network as an ideal target for HLA-DM (22). This
idea was experimentally demonstrated in several studies, which
in general highlighted a role for MHCII-peptide hydrogen bonds
near P1 pocket (23–25). A seeming discrepancy came from two
subsequent studies demonstrating that HLA-DM functions nor-
mally on MHCII-peptide complexes lacking conserved side-chain
hydrogen bonds (26, 27), but it is important to note that neither
study looked at the contribution of MHC main chain hydrogen
bonds as described in Stratikos et al. Nevertheless, these studies
suggested that individual hydrogen bonds may not be the key target
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for HLA-DM. A study of a MHCII mutant protein highly suscep-
tible to HLA-DM action revealed weakened MHC-peptide hydro-
gen bonding, as shown by a novel hydrogen-deuterium exchange
mass spectrometry assay, and structural alterations (discussed
below), suggesting a connection between conformational features
of MHCII-peptide complex, the MHCII-peptide hydrogen bond
network, and HLA-DM susceptibility (28).
CONFORMATIONAL HETEROGENEITY OF MHCII-PEPTIDE
COMPLEXES IN HLA-DM SUSCEPTIBILITY
Peptide-free MHCII molecules and certain MHCII variants loaded
with peptides can adopt conformations distinct from the canonical
structure observed by X-ray crystallography as judged by hydro-
dynamic, spectroscopic, and electrophoretic criteria (29–34). A
role for these conformational changes in determining HLA-DM
susceptibility has been appreciated more recently (28, 35–39).
A recent crystal structure of a MHCII variant with increased
HLA-DM affinity revealed conformational lability in the alpha
310 helical and extended region near the N-terminal end of the
bound peptide (28). Similar but smaller changes can be observed
in crystal structures of certain MHCII-peptide complexes (34). A
model for HLA-DM-mediated peptide exchange was presented, in
which transient or low-abundant MHCII-peptide conformers are
targeted by HLA-DM.
INSIGHT FROM RECENT HLA-DM-HLA-DO AND
HLA-DM-HLA-DR1 STRUCTURES
Recently, two X-ray crystal co-structures of HLA-DM bound to
MHCII protein targets have helped to illuminate the mechanism
of HLA-DM-mediated peptide exchange. In one, HLA-DM was
bound to HLA-DO, a natural inhibitor of HLA-DM (40). In the
other, HLA-DM was bound to HLA-DR1, a common MHCII
allele, for which a truncated peptide was covalently trapped in
the C-terminal side of the peptide binding site (41). In both cases
HLA-DM binds to the MHCII protein in a side-by-side arrange-
ment, with HLA-DM riding slightly above of the N-terminal side
of the MHCII-peptide binding groove (Figure 1).
HLA-DO is a non-classical MHCII protein that forms a sta-
ble complex with HLA-DM and inhibits HLA-DM function,
in vitro (42–44), and in vivo (45). In the HLA-DM-HLA-DO
structure, HLA-DO adopts an overall topology highly similar
to that of classical MHCII molecules such as HLA-DR1, with
substantial alpha subunit alternations (40). The key differences
are located in the 310 helix and extended strand region of the
alpha subunit, with HLA-DO residues αW43 and αF51 flipped
out from their usual partially buried conformations to interact
directly with HLA-DM. In addition, αF54 has moved into the
P1 pocket, possibly giving insight into how empty MHCII is sta-
bilized after peptide release (32). Given the fact that HLA-DM
does not form stable complex with classical MHCII molecules,
and the high structural similarity between HLA-DO and classical
MHCII molecules, the HLA-DM-HLA-DO interactions may rep-
resent an intermediate stage during HLA-DM catalyzed peptide
exchange from MHCII. This idea was supported by the almost
identical match of HLA-DM and MHCII residues implicated by
mutagenesis in the catalytic mechanism (33, 46, 47), and HLA-
DM and HLA-DO residues found in the interface in the crystal
structure (40).
FIGURE 1 | Overview of HLA-DM-HLA-DO and HLA-DM-HLA-DR1
structures. (A) Side view (left) and top view (right) of HLA-DM-HLA-DO
structure (PDB ID: 4IOP). HLA-DMα is colored green, HLA-DMβ blue,
HLA-DOα pink, and HLA-DOβ yellow. (B) Side view (left) and top view
(right) of HLA-DM-HLA-DR1 structure (PDB ID: 4FQX). HLA-DM is colored
the same, HLA-DR1α orange, and HLA-DR1β magenta. The peptide
(colored magenta) is located in the C-terminal end of the peptide binding
groove.
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The structure of HLA-DM bound to HLA-DR1 carrying a
covalently linked truncated peptide (41) also provides a model
of an intermediate in HLA-DM-mediated peptide exchange. As
in the HLA-DM-HLA-DO structure, αW43 in HLA-DR1 rotates
out of the lateral wall of P1 pocket to directly interact with HLA-
DM by forming a hydrogen bond with HLA-DM αN125. The
αW43 flip is accompanied by a conformational change in MHCII
alpha 310 helix and extended strand region (α46–α55) adjacent to
the P1 pocket. Although HLA-DO also exhibits conformational
changes in this region when bound to HLA-DM, the conforma-
tion adopted is different (Figure 2). In addition, HLA-DR1αF51 in
the HLA-DM-HLA-DR1 structure, rather than HLA-DO αF54 in
the HLA-DM-HLA-DO structure, repositions into the P1 pocket
to stabilize empty MHCII. It is possible that the three views of
the MHCII extended strand region observed in the various crys-
tal structures represent different conformers from an ensemble
adopted by a highly dynamic region.
Pos et al. suggested a model for HLA-DM-mediated peptide
exchange based on the HLA-DM-HLA-DR1 structure. In that
model, the N-terminus of a bound peptide dissociates from the
P1 pocket, allowing HLA-DR1 αW43 to flip out and interact with
HLA-DM. Meanwhile, HLA-DR1αF51 rotates into P1 pocket to
stabilize partially empty HLA-DR1. An exchange peptide with a
hydrophobic N-terminus could compete with HLA-DR1 αF51 for
the binding to P1 pocket, and displace HLA-DM and the original
peptide, reversing the conformational changes.
OUTSTANDING QUESTIONS IN HLA-DM-MEDIATED PEPTIDE
EXCHANGE
It is important to understand the process of HLA-DM-mediated
peptide exchange, which is crucial for determining HLA-DM bind-
ing and susceptibility, and how peptide sequence relates to those
properties. Proposed models agree on some aspects but differ in
important ways on others. General agreement has been reached on
the general structure of an intermediate in the peptide exchange
reaction, in which HLA-DM is bound to MHCII in an altered
conformation, involving a reorganized 310 helix and extended
strand region of the MHC II alpha subunit with disruption of
MHCII-peptide hydrogen bonds, blockage of the P1 pocket, and
inhibition of peptide binding. However, the disposition of aro-
matic residues in the P1 region, particularly αF51 and αF54, is not
clear, and whether or not changes occur in the C-terminal side of
FIGURE 2 | Conformational changes in the alpha 310 helix and
extended strand region. (A) Overlay of HLA-DO from HLA-DM-HLA-DO
structure with HLA-DR1-HA306-318 (PDB ID:1DLH). HLA-DMα is colored
green, HLA-DOα pink, HLA-DOβ yellow, and HLA-DR1 gray. (B) Overlay of
HLA-DR1 from HLA-DM-HLA-DR1 structure with HLA-DR1-HA306-318.
HLA-DMα is colored green, HLA-DR1α, and HLA-DR1β from
HLA-DM-HLA-DR1 orange and magenta, respectively, and HLA-DR1 from
HLA-DR1-HA306-318 gray. The peptide (colored magenta) is covalently
linked by a disulfide bond between a cysteine at peptide position P6 and
HLA-DR1 αV65C. Orientations and movements of important aromatic
residues in the vicinity of the P1 site are highlighted in (A) and (B).
Conformations of alpha 310 helix and extended strand region are shown
for (C) HLA-DR1 bound with an influenza peptide (HA306-318),
(D) HLA-DO bound with HLA-DM, and (E) HLA-DR1 bound with HLA-DM.
Each subunit is colored the same as above. In (C) HLA-DR1 αW43 points
into P1 pocket while αF51 and αF54 both point out; in (D) HLA-DO αW43
flips out to interact with αN125 from HLA-DM, while αF54 moves to the
P1 pocket; in (E) HLA-DR1 αW43 also flips out to interact with αN125 from
HLA-DM, while αF51 not αF54 moves to the P1 pocket. Other important
residues are also indicated in each panel.
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peptide binding groove remains elusive. Also whether peptide is
bound in the intermediate complex has not been tested directly
and currently is not known.
The mechanism by which a HLA-DM-bound intermediate
resolves to yield an exchanged MHCII-peptide complex also is
not clear. One outstanding question is in whether the exchanging
peptide binds dominantly via P1 pocket competition, or through
interactions throughout the entire peptide binding groove. It is
important to understand how peptide sequence determines the
ability to be exchanged onto MHCII during antigen presentation,
as this appears to be the crucial factor for epitope selection. A
model involving a tetramolecular HLA-DM-MHCII-two peptide
intermediate was proposed based on kinetics and spin-label studies
(48). This model was suggested to explain observations of acceler-
ated release of pre-bound peptide in the presence of free exchange
peptide (49–51).
CONCLUSION
Previous efforts and particularly two recent co-structures have
shed light on the mechanism of HLA-DM-mediated peptide
exchange. HLA-DM appears to promote peptide exchange by
disrupting the MHCII-peptide hydrogen bond network at the
N-terminal end of the peptide binding groove, and by dis-
rupting MHCII-peptide interactions in the P1 pocket through
stabilization of an altered conformation of the 310 helix and
extended strand region. Important questions still remain about
how the sequence of MHCII-bound peptide determines MHCII-
conformation, HLA-DM susceptibility, and peptide exchange
function.
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